Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Plasma Kallikrein Contributes to Ellagic Acid-Induced Coagulation in the Absence of FXI By Activating Factor IX

Mayken Visser, Rene van Oerle, Hugo ten Cate, MD PhD, Volker Laux, PhD, Stefan Heitmeier, PhD, Henri M.H. Spronk, PhD

Blood (2019) 134 (Supplement_1): 1106.

https://doi.org/10.1182/blood-2019-131738

Published: 2019

Journal Articles

Pre-Analysis for Hemostatic Effect of Bypassing Agents in Hemophilia a Patients with Inhibitors Under the Emicizumab Prophylaxis By Global Assays

Shoko Furukawa, MD, Keiji Nogami, MD PhD, Tomoko Matsumoto, PhD, Ryu Kasai, MSc, Midori Shima, MD PhD

Blood (2018) 132 (Supplement 1): 3793.

https://doi.org/10.1182/blood-2018-99-114355

Published: 2018

Journal Articles

Assessment of Emicizumab-Driven Clot Stability in Hemophilia a Model

Kenichi Ogiwara, MD PhD, Hiroki Horiuchi, Keiji Nogami, MD PhD, Takehisa Kitazawa, DVM, Midori Shima, MD PhD

Blood (2018) 132 (Supplement 1): 2478.

https://doi.org/10.1182/blood-2018-99-118379

Published: 2018

Journal Articles

A Modified Thrombin Generation Analysis to Measure the Plasma Coagulation Potency in the Presence of Anti-FIXa/FX Bispecific Antibody, Emicizumab

Kenichi Ogiwara, MD PhD, Keiji Nogami, MDPhD, Tomoko Matsumoto, PhD, Mariko Noguchi-Sasaki, PhD, Tetsuhiro Soeda, PhD, Naoki Matsumoto, PhD, Michinori Hirata, PhD, Midori Shima, MD PhD

Blood (2018) 132 (Supplement 1): 1200.

https://doi.org/10.1182/blood-2018-99-118504

Published: 2018

Journal Articles

Activity of a FIX-Padua Transgene Product in Commonly Used FIX:C One-Stage and Chromogenic Assay Systems Following PF-06838435 (SPK-9001) Gene Delivery

Mary Robinson, PhD, Lindsey A. George, MD, Benjamin J. Samelson-Jones, MD PhD, Valder R Arruda, MD PhD, Katherine A. High, MD, Marcus E Carr, MD PhD, Stefan Tiefenbacher, PhD

Blood (2018) 132 (Supplement 1): 2198.

https://doi.org/10.1182/blood-2018-99-119616

Published: 2018

Journal Articles

A Novel Hemostatic Monitoring System Convertible to FVIII Activity Based on Non-Activated ROTEM (NATEM) for Hemophilia a Patients during Emicizumab Prophylaxis

Koji Yada, MD PhD, Keiji Nogami, MD PhD, Ryu Kasai, MSc, Midori Shima, MD PhD

Blood (2018) 132 (Supplement 1): 3782.

https://doi.org/10.1182/blood-2018-99-117877

Published: 2018

Journal Articles

Increasing of Ternary Complex Formation By Predominant Accumulation of Factor (F)X Accompanied By Increase of Fixa Contributes to Enhancement of Clotting Function By Apcc in Combination with Emicizumab

Koji Yada, MD PhD, Keiji Nogami, MDPhD, Tomoko Matsumoto, PhD, Takehisa Kitazawa, DVM, Midori Shima, MDPhD

Blood (2017) 130 (Supplement 1): 3658.

https://doi.org/10.1182/blood.V130.Suppl_1.3658.3658

Published: 2017

Journal Articles

A Novel Clot Waveform Analysis to Measure the Plasma Coagulation Potency in the Presence of Anti-Fixa/Fx Bispecific Antibody, Emicizumab

Keiji Nogami, MD PhD, Tomoko Matsumoto, PhD, Yuka Tabuchi, Tetsuhiro Soeda, PhD, Nobuo Arai, Takehisa Kitazawa, Hidenari Takaoka, Kunihiro Hattori, PhD, Midori Shima, MD PhD

Blood (2016) 128 (22): 1388.

https://doi.org/10.1182/blood.V128.22.1388.1388

Published: 2016

Journal Articles

ACE910 Facilitates Its Hemostatic Effect with the Lower Concentration of Factor X Than That Required for Factor VIIa-Driven Coagulation

Koji Yada, MD PhD, Keiji Nogami, MD PhD, Takehisa Kitazawa, DVM, Kunihiro Hattori, PhD, Midori Shima, MD PhD

Blood (2015) 126 (23): 1077.

https://doi.org/10.1182/blood.V126.23.1077.1077

Published: 2015

Journal Articles

Analysis of Racial Disparity in Plasma of Healthy Volunteers Using Rotational Thromboelastometry Reveals Higher Prothrombotic Profile in African Americans

Maissaa Janbain, MD, Walter J Liszewski, BA, Cindy A Leissinger, MD

Blood (2014) 124 (21): 5972.

https://doi.org/10.1182/blood.V124.21.5972.5972

Published: 2014

Journal Articles

A Biomarker Assay For The Detection Of Contact System Activation

Ryan R Faucette, Marco Cicardi, MD, Chiara Suffritti, PhD, Jon A Kenniston, Daniel J Sexton, Burt Adelman

Blood (2013) 122 (21): 2347.

https://doi.org/10.1182/blood.V122.21.2347.2347

Published: 2013

Journal Articles

Comparison Of Plasma Kallikrein Inhibition By The Endogenous C1-Inhibitor Versus DX-2930, a Monoclonal Antibody Inhibitor

Daniel J Sexton, Jon A Kenniston, Ryan R Faucette, Andrew E Nixon, Chris TenHoor, Yung Chyung, Burt Adelman

Blood (2013) 122 (21): 1066.

https://doi.org/10.1182/blood.V122.21.1066.1066

Published: 2013

Journal Articles

An Optimal Monitoring On Bypassing Therapy for Hemophilia A Patients with Inhibitor Using aPTT-Based Clot Waveform Analysis with the Presence of Minimal TF

Junka Haku, MD, Kenichi Ogiwara, MD, PhD, Tomoko Matsumoto, PhD, Koji Yada, MD, Midori Shima, MD, PhD, Keiji Nogami, MD, PhD

Blood (2012) 120 (21): 3382.

https://doi.org/10.1182/blood.V120.21.3382.3382

Published: 2012

Journal Articles

Coagulation Functions with Clinical Phenotype and Inhibitory Mechanisms in Acquired Factor V Inhibitors.

Tomoko Matsumoto, PhD, Keiji Nogami, MD, PhD, Kenichi Ogiwara, MD, PhD, Midori Shima, MD, PhD

Blood (2012) 120 (21): 2232.

https://doi.org/10.1182/blood.V120.21.2232.2232

Published: 2012

Journal Articles

Waveform Analysis Extends the Capabilities of aPTT and PT Clotting Assays for Detecting Factor Deficiency and Monitoring Procoagulant Drug Therapy

Lilley Leong, PhD, MS, Xiaoqiao Jiang, BS, Jill Cifrese, MS, John E. Murphy, PhD, Jesper Haaning, PhD, Timothy Myles, PhD

Blood (2011) 118 (21): 1205.

https://doi.org/10.1182/blood.V118.21.1205.1205

Published: 2011

Journal Articles

The Tick Protein Ir-Cpi Efficiently Delays Contact Pathway Induced Thrombin Generation and Displays In Vivo Antithrombotic Activity

Severine Robert, Yves Decrem, Géraldine Rath, Chantal Dessy, Olivier Feron, François Mullier, Bernard Chatelain, Philippe Devel, Jean-Michel Dogné, Edmond Godfroid

Blood (2010) 116 (21): 3336.

https://doi.org/10.1182/blood.V116.21.3336.3336

Published: 2010

Journal Articles

Determination of Coagulation Functions and Inhibitory Mechanisms In Acquired Hemophilia A with Type 1 and Type 2 Inhibitors.

Tomoko Matsumoto, Keiji Nogami, MD, PhD, Kenichi Ogiwara, MD, Nobuyuki Tsujii, MD, Midori Shima, MD, PhD

Blood (2010) 116 (21): 3666.

https://doi.org/10.1182/blood.V116.21.3666.3666

Published: 2010

Journal Articles

Determination for Coagulation Functions and Novel Inhibitory Mechanisms in Acquired Hemophilia A with Type 2 Inhibitors.

Tomoko Matsumoto, Keiji Nogami, Kenichi Ogiwara, Katsumi Nishiya, Masahiro Takeyama, Midori Shima

Blood (2009) 114 (22): 3483.

https://doi.org/10.1182/blood.V114.22.3483.3483

Published: 2009

Journal Articles

Thromboelastometry in Patients Receiving Platelet Transfusion after Chemotherapy.

Henning Dehmel, Andreas Tiede, MD, PhD, Silvia Horter, Arnold Ganser, MD, Mario von Depka, MD

Blood (2004) 104 (11): 3630.

https://doi.org/10.1182/blood.V104.11.3630.3630

Published: 2004

Journal Articles

A hitherto undescribed plasma factor acting at the contact phase of blood coagulation (Flaujeac factor): case report and coagulation studies

MJ Lacombe, B Varet, JP Levy

Blood (1975) 46 (5): 761–768.

https://doi.org/10.1182/blood.V46.5.761.761

Published: 1975

NARROW

Plasma Kallikrein Contributes to Ellagic Acid-Induced Coagulation in the Absence of FXI By Activating Factor IX

Pre-Analysis for Hemostatic Effect of Bypassing Agents in Hemophilia a Patients with Inhibitors Under the Emicizumab Prophylaxis By Global Assays

Assessment of Emicizumab-Driven Clot Stability in Hemophilia a Model

A Modified Thrombin Generation Analysis to Measure the Plasma Coagulation Potency in the Presence of Anti-FIXa/FX Bispecific Antibody, Emicizumab

Activity of a FIX-Padua Transgene Product in Commonly Used FIX:C One-Stage and Chromogenic Assay Systems Following PF-06838435 (SPK-9001) Gene Delivery

A Novel Hemostatic Monitoring System Convertible to FVIII Activity Based on Non-Activated ROTEM (NATEM) for Hemophilia a Patients during Emicizumab Prophylaxis

Increasing of Ternary Complex Formation By Predominant Accumulation of Factor (F)X Accompanied By Increase of Fixa Contributes to Enhancement of Clotting Function By Apcc in Combination with Emicizumab

A Novel Clot Waveform Analysis to Measure the Plasma Coagulation Potency in the Presence of Anti-Fixa/Fx Bispecific Antibody, Emicizumab

ACE910 Facilitates Its Hemostatic Effect with the Lower Concentration of Factor X Than That Required for Factor VIIa-Driven Coagulation

Analysis of Racial Disparity in Plasma of Healthy Volunteers Using Rotational Thromboelastometry Reveals Higher Prothrombotic Profile in African Americans

A Biomarker Assay For The Detection Of Contact System Activation

Comparison Of Plasma Kallikrein Inhibition By The Endogenous C1-Inhibitor Versus DX-2930, a Monoclonal Antibody Inhibitor

An Optimal Monitoring On Bypassing Therapy for Hemophilia A Patients with Inhibitor Using aPTT-Based Clot Waveform Analysis with the Presence of Minimal TF

Coagulation Functions with Clinical Phenotype and Inhibitory Mechanisms in Acquired Factor V Inhibitors.

Waveform Analysis Extends the Capabilities of aPTT and PT Clotting Assays for Detecting Factor Deficiency and Monitoring Procoagulant Drug Therapy

The Tick Protein Ir-Cpi Efficiently Delays Contact Pathway Induced Thrombin Generation and Displays In Vivo Antithrombotic Activity

Determination of Coagulation Functions and Inhibitory Mechanisms In Acquired Hemophilia A with Type 1 and Type 2 Inhibitors.

Determination for Coagulation Functions and Novel Inhibitory Mechanisms in Acquired Hemophilia A with Type 2 Inhibitors.

Thromboelastometry in Patients Receiving Platelet Transfusion after Chemotherapy.

A hitherto undescribed plasma factor acting at the contact phase of blood coagulation (Flaujeac factor): case report and coagulation studies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only